Narcotics prosecutors say a NYC hospital's former pharmacy chief stole nearly 200,000 oxycodone pills over more than five years.» Read More
The largest U.S. pharmacy benefit manager, Express Scripts, is cutting back on compounded medications, saying most are ineffective or overpriced.
Massachusetts is expected to add almost 400 jobs in biotech manufacturing by 2016. CNBC's Mary Thompson reports Quincy College aims to fill some of those jobs with a new program.
CNBC's Mary Thompson reports Quincy College in Massachusetts is training students with hands-on experience for jobs in the biotech industry.
Pfizer paid a "nominal fee" to cover expenses related to the facility inspection, and to obtain a certification, a Pfizer spokeswoman said.
Hedge fund Paulson & Co has amassed a large stake in Allergan and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals.
The U.S. Food and Drug Administration warned that popular acne products can cause rare but serious and life-threatening allergic reactions.
Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.
A combination of Vertex drugs met the goals of two late-stage clinical trials in cystic fibrosis, setting the stage for Vertex to apply for approval.
CNBC's Meg Tirrell reports the pharmaceutical company has developed a new drug that significantly improves lung function in the treatment of cystic fibrosis.
A U.S. Senate panel asked the Centers for Disease Control and Prevention to explain the breach that exposed many to live anthrax, a deadly pathogen.
Vertex's Kalydeco was the first medicine to address the underlying genetic cause. A new drug combination, Kalydeco and Lumacaftor, is designed to treat many additional cases.
Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.
Genetics startup 23andMe said it is one step closer to resuming sales of its full-fledged health product.
Researchers have discovered that an FDA-approved arthritis drug may hold the secret to curing hairlessness.
Basically, the patient makes his own drug, says Stephane Bancel, Moderna Therapeutics CEO explaining how his company is revolutionizing mRNA technology.
CNBC's Julia Boorstin takes a look at how Moderna Therapeutics is disrupting the biotech world.
CNBC's Jim Cramer gives his call on the "only really legitimate marijuana stock" in the market and a food company.
US Agriculture Secretary is confident an approved vaccine would help fight a deadly virus that has killed millions of pigs.
Valeant said it plans to launch an exchange offer to Allergan shareholders this week, soliciting proxies to call for a meeting to discuss its offer.
Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.
Get the best of CNBC in your inbox